British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. Issue 2 (19th January 2021)

• Record Type: Journal Article
• Authors: Sundar, Sudha; Manchanda, Ranjit; Gourley, Charlie; George, Angela; Wallace, Andrew; Balega, Janos; Williams, Sarah; Wallis, Yvonne; Edmondson, Richard; Nicum, Shibani; Frost, Jonathan; Attygalle, Ayoma; Fotopoulou, Christina; Bowen, Rebecca; Bell, Dani; Gajjar, Ketankumar; Ramsay, Bruce; Wood, Nicholas J; Ghaem-Maghami, Sadaf; Miles, Tracie; Ganesan, Raji
• Is Part Of: International journal of gynecological cancer. Volume 31:Issue 2(2021)
• Page Start: 272
• Page End: 278
• Publication Date: 2021-01-19
• Subjects: BRCA1 protein -- BRCA2 protein -- fallopian tube neoplasms -- ovarian neoplasms; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2020-002112
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.